The application of antagomiR-21 demonstrated positive results in sensitizing cells to imatinib, inducing cancer cell apoptosis, and inhibiting the phosphatidylinositol-3-OH kinase/AKT (PI3K/AKT) pathway [190]. The gene discussed is AKT1; the disease is cancer.